

Interaction between COX-1 and COX-2 increases susceptibility to ischemic stroke in a Chinese population

Lei Zhao

Sichuan University West China Hospital

Jinghuan Fang

Sichuan University West China Hospital

Muke Zhou

Sichuan University West China Hospital

Jie Zhou

Sichuan University West China Hospital

Lihua Yu

Sichuan University West China Hospital

Ning Chen

Sichuan University West China Hospital

Li He (✉ heli2003new@126.com)



Sichuan University West China Hospital <https://orcid.org/0000-0003-0522-9296>

Research article

Keywords: Ischemic stroke; COX-1; COX-2; single nucleotide polymorphism; gene-gene; interaction

Posted Date: March 1st, 2019

DOI: <https://doi.org/10.21203/rs.2.423/v1>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Version of Record: A version of this preprint was published on November 17th, 2019. See the published version at <https://doi.org/10.1186/s12883-019-1505-1>.

Abstract

Background Mutations of cyclooxygenase gene (COX gene) may increase the susceptibility of ischemic stroke. We investigated five variants (rs5788, rs1330344, rs3842788, rs20417, and rs689466) of two COX genes to explain the association between these polymorphisms and ischemic stroke risk determine whether gene–gene interaction between these genes increase the susceptibility of ischemic stroke or its subtype. Methods A total of 1981 study subjects (1078 cases and 903 control subjects) were recruited. The interaction of multiple factors was investigated using Multifactor Dimensionality Reduction and additive effect of single nucleotide polymorphisms on ischemic stroke or its subtypes were analyzed by multiple factor logistic regression. Results At COX-1(rs1330344), AA genotype carriers had a lower susceptibility of ischemic stroke (OR=0.657, 95%CI= 0.437-0.988, P = 0.044), and A allele carriers had a lower susceptibility of ischemic stroke (OR=0.812, 95%CI= 0.657-0.978, P = 0.029). At COX-1(rs3842788), AA genotype carriers had a higher susceptibility of ischemic stroke (OR =5.203, 95% CI=1.519-5.159, P =0.016). At COX-2 (rs689466), AA genotype carriers had a higher susceptibility of large-artery atherosclerosis (OR =1.404, 95% CI=1.019-1.934, P =0.038). COX-1(rs1330344, rs3842788) and COX-2 rs689466 interacted in SVO, but had no additive effect with ischemic stroke or its subtypes. Conclusions At rs1330344, AA genotype may reduce the susceptibility of ischemic stroke. At rs3842788, AA genotype may increase the susceptibility of ischemic stroke. At rs689466, AA genotype may increase the susceptibility of large-artery atherosclerosis (LAA). COX-1(rs1330344, rs3842788) and COX-2 rs689466 interacted in small vessel occlusion (SVO), but had no additive effect with ischemic stroke or its subtypes.

Background

Stroke is a common cerebrovascular disease, which is the second cause of disability and mortality worldwide. The most common type of stroke is ischemic stroke, which accounts for approximately 80% of all stroke cases. [1, 2] As a complex disease, ischemic stroke was characterized by several etiological factors and likely affected by various genes, environments, lifestyles, and other causes; which could produce complex high-order interactions to this disease. [3-6]

Genome-wide association studies (GWAS) have verified various ischemic stroke-associated inflammatory factor genes, including cyclooxygenase or prostaglandin oxidase. COX is a bifunctional enzyme with oxidase and catalase activities and a key enzyme in the arachidonic acid metabolism of prostaglandins (PGs) and thromboxane A₂ (TXA₂). Prostaglandin E₂(PGE₂) is involved in inflammation, and TXA₂ is implicated in platelet aggregation and vasoconstriction. [7] COX gene is closely related to the cause of ischemic stroke, elucidating its genetic mechanism is of great significance in exploring the risk prediction of ischemic stroke and developing new targets for drug treatment. There are two forms of COX in the human body currently: COX-1 and COX-2. One is the structural type COX-1, which is stably expressed in normal cells, catalyzes the formation of PGs to maintain normal physiological function, regulates platelet functional activity and coagulation function. And the second is induced type COX-2, which is only highly expressed when the cells affected by various factors such as oncogenes, cytokines, growth factor, endotoxin, carcinogen, catalyzes prostaglandin E₂ (PGE₂) to participates in physiological and pathological processes of inflammation or tumor. [8] Based on this physiological role, we hypothesized that the mutation of COX gene may be associated with the susceptibility of ischemic stroke. Maree et al. [9] has demonstrated that COX-1 gene mutation can change the platelet aggregation

rate and affect thrombus formation, therefore it will cause thrombotic diseases such as ischemic stroke by regulating Arachidonic acid (AA) metabolic processes. GWAS and other related studies have revealed that multiple SNPs of a COX-2 gene can influence inflammatory processes in the human body by regulating the expression of its products, such as PGs increasing the formation of plaque.^[10] And there was a study showed COX-2 is an ischemic stroke-susceptible gene in African–American and European populations.^[11] However, researches of COX-1 and COX-2 remain controversial. There is no specific locus associated with ischemic stroke, and the results vary from population to population.^[12-17] It maybe because the statistical significance of single SNP studies on ischemic stroke has failed to explain the association between SNPs in the same gene.

Therefore, the interacting effects of multiple SNPs on ischemic stroke should be considered.^[18] We conducted a large-sample case-control study to investigate the association of five variants (rs5788, rs1330344, rs3842788, rs20417, and rs689466) of COX-1 and COX-2 genes with ischemic stroke and to investigate the pattern of genetic variation within *COX* and to explore whether gene–gene interactions between these genes increase the susceptibility of ischemic stroke or its subtypes.

Methods

1. Samples

Genomic DNA was isolated from morning fasting peripheral venous blood of 1078 cases of patients with diagnosed of ischemic stroke (ischemic stroke group) and 903 cases of non-ischemic stroke subjects (control group) from the Han racial/ethnic groups in Mainland China. All the patients came from the same region of the Han population and were matched in terms by gender and age. Patients' information was obtained from the stroke database of the Neurology Department of West China Hospital.

The inclusion criteria was as follows: 1) age \geq 40 years old; 2) the diagnose of ischemic stroke was confirmed by brain magnetic resonance imaging according to WHO diagnostic criteria.^[19] Exclusion criteria was as follows: 1) hemorrhagic stroke, or recurrent ischemic stroke; 2) other etiologies of ischemic stroke: stroke of other determined etiology (SOD), or stroke of undetermined etiology (SUD); 3) cerebrovascular malformation or brain tumor. In this study, ischemic stroke group were divided into three subtypes: large-artery atherosclerosis (LAA), cardioembolic stroke (CES), and small vessel occlusion (SVO) according to TOAST typing.^[20] We selected the patients without stroke history and none cerebral infarction lesions in CT/MRI into control group. The purpose of the study was described in detail, and informed consents were obtained from all the participants. This study was approved by the Ethics Review Committee of West China hospital, Sichuan University.

2. Demographic data and characteristics of participants

The following demographic data and relevant characteristics were obtained: hypertension (SBP \geq 140 mmHg/DBP \geq 90 mmHg) or medication intake, diabetes (random blood glucose \geq 7.0 mmol/L) or medication intake, coronary heart disease, hyperlipidemia (cholesterol, TC \geq 5.62 mmol/L/, or triglyceride, TG \geq 1.92 mmol/L) or medication intake,^[21] smoking (\geq 10 cigarettes per day, smoking age $>$ 1 years, or duration of smoking cessation \leq 3 years),^[22] and drinking ($>$ 50 ml/d, $>$ 1 year). Other data were also collected from patients' medical records.

3. Genotype determination

Genomic DNA was isolated with an AxyPrep™ blood genomic DNA maxiprep kit (Axygen Biosciences, USA). Five SNPs of *COX-1* and *COX-2* were retrieved from the NCBI database (<http://www.ncbi.nlm.nih.gov/SNP>). Five SNPs selected for our study (based on potential functional significance and minor allele frequency of >0.10)—*COX-1-644C/A* (*rs5788*), *COX-1-1676G/A* (*rs1330344*), *COX-1-128G/A* (*rs3842788*), *COX-2-765G/C* (*rs20417*), and *COX-2-1195G/A* (*rs689466*).^[23] Genotyping was performed in a blinded manner by K-Biosciences (Herts, UK) (<http://www.kbioscience.co.uk/>) using a competitive allele-specific PCR system (KASPar).

4. Statistical analysis

Three common genetic models are used in related studies: dominant, recessive, and additive model. In this study, each SNP contained the major allele A and minor allele B. AB+BB versus AA was calculated by the dominant model, BB versus AB+AA was determined by the recessive model, and AB versus AA or BB versus AA was examined by the additive model. The three models for each site were statistically analyzed by SPSS 19.0 (SPSS Inc., Chicago, IL, USA). The frequencies of each allele and genotype were calculated by performing χ^2 test and described as mean \pm SD. The Hardy–Weinberg equilibrium of the five polymorphic distributions of the patients and controls was evaluated through a chi-square goodness-of-fit test. The correlation of the SNPs and their cumulative effects on ischemic stroke were examined through multiple factor logistic regression after adjusted related risk factors, such as gender, age, smoking, and hypertension. The interaction of multiple factors was investigated using MDR version 3.0.2 (<http://sourceforge.net/projects/mdr/>). Odds ratios were calculated with 95% confidence intervals. $P < 0.05$ was considered statistically significant.

Results

1. Study Population and Baseline Characteristics

There were in total 1981 subjects, including 1078 cases of ischemic stroke patients and 903 cases of control group. The clinical characteristics of the patients and controls were listed in **Table 1**. The proportion was higher of hypertension, diabetes, hyperlipidemia, and coronary heart disease, smoking in patient group, and also higher fibrinogen level, lower high-density lipoprotein cholesterol (HDL-C) level and lower blood platelet (PLT) level. There were significant differences of the proportion of men in our study between the case group and the control group. LDL-C level between two groups had no significant difference. These risk factors such as sex, hypertension, diabetes, smoking, alcohol consumption, triglyceride level, platelet level and fibrinogen level were associated with the three subtypes— LAA, CES and SVO groups of ischemic stroke, and the distribution of the three groups was also statistical significantly different.

2. Genotype and allele frequency distributions of SNPs in ischemic stroke and controls **Table 2**

At *COX-1* (*rs5788*) and *COX-2* (*rs20417*), no significant differences were observed in genotype and allele frequencies between the ischemic stroke group including the three subtypes (LAA, CES, SVO) and the control group, even after we using multivariate analysis by adjusting for age, gender and related risk factors.

At *COX-1*(*rs1330344*), compared to the GG genotype, the AA genotype carriers had a lower susceptibility of ischemic stroke, and this difference remained significant in multivariate analysis by adjusting for age, gender

and traditional risk factors ($OR = 0.657$, $95\% CI = 0.437-0.988$, $P = 0.044$). And the AA genotype carriers also had a lower susceptibility of CES or SVO ($OR = 0.506$, $95\% CI = 0.262-0.978$, $P = 0.043$; $OR = 0.616$, $95\% CI = 0.382-0.995$, $P = 0.048$). Meanwhile, compared to the G allele, the A allele carriers had a lower susceptibility of ischemic stroke, and this difference remained significant in multivariate analysis by adjusting for age, gender and traditional risk factors ($OR = 0.812$, $95\% CI = 0.675-0.978$, $P = 0.029$). And the A allele carriers also had a lower susceptibility of LAA or CES ($OR = 0.778$, $95\% CI = 0.618-0.981$, $P = 0.034$; $OR = 0.702$, $95\% CI = 0.518-0.951$, $P = 0.023$).

At *COX-1(rs3842788)*, compared to the G allele carriers genotype (GG+GA), the AA genotype carriers had a higher susceptibility of ischemic stroke, this difference remained significant in multivariate analysis by adjusting for age, gender and traditional risk factors ($OR = 5.203$, $95\% CI = 1.519-5.159$, $P = 0.016$). And the AA genotype carriers also had a higher susceptibility of CES or SVO ($OR = 9.821$, $95\% CI = 2.754-12.832$, $P = 0.041$; $OR = 4.603$, $95\% CI = 1.220-5.201$, $P = 0.025$).

At *COX-2(rs689466)*, compared to the G allele carriers genotype (GG+GA), the AA genotype carriers had a higher risk of LAA, this difference remained significant in multivariate analysis by adjusting for age, gender and traditional risk factors ($OR = 1.404$, $95\% CI = 1.019-1.934$, $P = 0.038$).

3. MDR analysis

Gene-gene interactions were investigated for ischemic stroke and its subtypes by using MDR, and two models of SVO were statistically significant (*Permutation test P value* <0.05, **Table 3**). Among all gene-gene interaction models evaluated, a two-locus model (rs1330344 and rs689466) with the maximum cross-validation consistency (CVC: 10/10) and testing accuracy (0.5436) was regarded as the overall best model in our study. In addition, the best three-locus model (including rs1330344, rs3842788 and rs689466) had a maximum CVC (10) and higher testing accuracy (0.5376).

4. Additive effect analysis

We used multiple logistic regression analysis to analyze the correlation between the additive effect of COX-1 (rs1330344, rs3842788), COX-2 (rs689466) and ischemic stroke. Setting: the risk allele for each locus was 1, and the remainder was 0. We compared the carrying 1, 2, 3 risk loci to carry 0 risk loci without taking into account the specific loci or genes, just carrying any polymorphic loci count. Compared with those carrying none of the variants, individuals carrying one variant, carrying two variants and carrying three variants had no significant differences of the risk of ischemic stroke or its subtypes. (**Table 4**)

Discussion

COX gene is closely related to the cause of ischemic stroke. COX-1 gene locates on chromosomes 9q32-q33.3 and contains 11 exons, COX-2 gene located on chromosomes 1q25.2-q25.3 and contains 10 exons.^[24] COX-1 participates in the normal physiological metabolism of the body and regulates platelet function and blood coagulation.^[25] COX-2 is only highly expressed when the cells affected by various factors such as oncogenes, cytokines, growth factor, endotoxin, carcinogen to participate in physiological and pathological processes of

inflammation or tumor.^[8] COX-2 expression is 10–20 times higher in patients with atherosclerotic plaques or inflammatory stimuli than in asymptomatic patients with arterial stenosis.^[26]

Our results showed that rs1330344 and rs3842788 appeared to contribute significantly to the occur of ischemic stroke, but the genotype and allele frequencies at rs5788 had no significant difference between ischemic stroke group and the control group. At rs1330344, AA genotype may reduce the susceptibility of ischemic stroke, and CES or SVO. Meanwhile, the A allele carriers also may reduce the susceptibility of ischemic stroke, LAA or CES at rs1330344. At rs3842788, the susceptibility of ischemic stroke was fivefold higher in the AA genotype than in the G allele carrier genotype (GG+GA, recessive model) the susceptibility of CES was higher by about 9.8 times; the risk of SVO was higher by about 4.6 times. A study of 859 ischemic stroke patients found that the rs5788 locus is not related to ischemic stroke in China, which was consistent with our results.^[14] They also suggested that the homozygotes of the minor allele at rs1330344 increase the risk of ischemic stroke recurrence, which was inconsistent with our findings. This maybe the type of ischemic stroke patients that we included was different with them, their study included patients with recurrent ischemic stroke, and all of the patients were classified as one type. Instead, our study included patients who had their first onset of ischemic stroke and grouped by the TOAST classification. Another study of 196 ischemic stroke patients in Korea revealed that the rs3842788 locus is not associated with ischemic stroke, and a study of 469 ischemic stroke patients in USA also got the same results, which were inconsistent with our results.^[15] These studies all had relatively few samples and involving different ethnic population. Large samples and multiethnic studies should be conducted to verify the association of rs1330344 and rs3842788 with ischemic stroke.

Our results showed that the genotype and allele frequencies at rs20417 had no significant difference between the ischemic stroke group and the control group. This conclusion is consistent with a meta-analysis of rs20417.^[16] There were two studies (411 ischemic stroke patients in China, 469 ischemic patients in USA) also found that rs20417 appear not to be associated with the development of ischemic stroke.^[27, 28] Meanwhile, Francesco et al.^[13] observed that the GC and CC genotypes of rs20417 are related to the pathogenesis of ischemic stroke, and C allele may be a genetic protective factor that reduces the incidence of ischemic stroke. Conversely, a study showed that the GC and CC genotypes were commonly found in African–American and European populations affected by ischemic stroke and suggested that COX-2 is an ischemic stroke-susceptible gene.^[11] In our study, the difference between ischemic stroke group and control group at rs20417 was not significant, this may due to population and genetic heterogeneity. However, research of rs20417 remains controversial. There were few study to research the association of COX(rs689466) with ischemic stroke, most studies focused on inflammation and cancer.^[29-31] In our study, compared to the G allele carriers genotype (GG+GA), the AA genotype carriers had a higher risk of LAA at *COX-2(rs689466)*. There were two studies of Chinese population (Zhejiang Province-224 patients with LAA and 329 patients with SVO,^[17] Beijing-93 patients with LAA and 117 patients with SVO^[32]) found that rs689466 was associated with susceptibility to ischemic stroke in a Chinese population. But the effects were confined to SVO among the stroke subtypes rather than to LAA which was dissimilar to our study. On the other hand, another study of 572 Chinese patients showed that rs689466 was not associated with ischemic stroke and its subtypes^[33].

We had got some statistically significant positive results from the single gene polymorphism research of COX-1 and COX-2 gene. But these results were not entirely consistent with existing research and cannot fully explain

the association between each polymorphism in the same gene. Therefore, we also conducted the study on the interaction between multiple loci in ischemic stroke. Our study found that COX-1(rs1330344, rs3842788) and COX-2 rs689466 are associated with SVO. Compared with those patients who do not carry any of the variants, individuals carrying one variant, two variants, and three variants had no significant difference between the ischemic stroke and the control groups. Our previous results showed that rs1330344 reduces the risk of ischemic stroke, including CES and SVO, whereas rs3842788 increases the risk of ischemic stroke, including CES and SVO, rs689466 increases the risk of LAA, and the three loci interact with SVO. Our study had several limitations of genetic and phenotypic heterogeneity, different regions, and various ethnic groups with different susceptibilities to the same disease. Our study only included the Han population in the southwest of China. As such, our findings should be further validated in different regions and different ethnic groups. Our study only examined two and three loci of the candidate genes and thus may be unable to cover the entire gene linkage disequilibrium signal. Hence, a linkage disequilibrium map of the gene should be constructed to clarify the relationship between this gene and the pathogenesis of ischemic stroke. The quantification of the environmental factors of ischemic stroke was relatively difficult. Thus, the role of the interaction of environmental factors was not considered in our study. Instead, this study was limited to two genes and three loci to explore the gene–gene interaction in ischemic stroke. Therefore, future studies on gene interaction should include environmental and epigenetic factors. A larger cohort of more races should also be established to cover more ischemic stroke-susceptibility genes and meta-GWAS results. Further studies should also be performed to enhance our understanding of the genetic structure of ischemic stroke, to investigate the molecular mechanism of ischemic stroke, and to provide a new angle for the diagnosis and treatment of ischemic stroke.

Conclusions

At rs1330344, AA genotype may reduce the susceptibility of ischemic stroke. At rs3842788, AA genotype may increase the susceptibility of ischemic stroke. At rs689466, AA genotype may increase the susceptibility of large-artery atherosclerosis (LAA). COX-1(rs1330344, rs3842788) and COX-2 rs689466 interacted in small vessel occlusion (SVO), but had no additive effect with ischemic stroke or its subtypes in a Han population from Southwest China.

Abbreviations

COX gene: cyclooxygenase gene

LAA: large-artery atherosclerosis

CES: cardioembolic stroke

SVO: small vessel occlusion

Declarations

Ethics approval and consent to participate

Our research was reviewed and approved by the Ethics Review Committee of West China hospital, Sichuan University. The patient consent was given in verbal form.

Consent for publication

No applicable.

Availability of data and material

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

No funding was received from any organization or individuals.

Authors' contributions

ZL, ZMK, YLH, CN and HL were responsible for the concept and design of the study. ZL, FJH and ZJ were responsible for collecting and analyzing the data. ZL was responsible for drafting the manuscript. FJH was responsible for the study coordination and interpretation of data. All authors participated in review and revision of the manuscript. All authors read and approval the final manuscript.

Acknowledgements

Not applicable.

References

- [1] Roger V L, *Heart disease and stroke statistics–2011 update: a report from the American Heart Association*. Circulation, 2011. **123**(4): p. e18-e209.
- [2] Yang G, Wang Y, Zeng Y, et al., *Rapid health transition in China, 1990–2010: findings from the Global Burden of Disease Study 2010*. Lancet, 2013. **9882**(9882): p. 1987-2015.
- [3] Matarin M, Singleton A, Hardy J, et al., *The genetics of ischaemic stroke*. J Intern Med, 2010. **267**(2): p. 139-55.
- [4] Rothwell P M, Coull A J, Giles M F, et al., *Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study)*. Lancet, 2004. **363**(9425): p. 1925-1933.
- [5] Rubattu S, Giliberti R, and Volpe M, *Etiology and pathophysiology of stroke as a complex trait* □. American Journal of Hypertension, 2000. **13**(10): p. 1139-1148.

- [6] Rosengren A, Hawken S, Ôunpuu S, et al., *Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study) : case-control study*. Lancet, 2004. **364**(9438): p. 953-62.
- [7] Warner T D, Mitchell J A, *Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic*. Faseb Journal Official Publication of the Federation of American Societies for Experimental Biology, 2004. **18**(7): p. 790-804.
- [8] Vane J, Bakhle Y, Rm, *Cyclooxygenases 1 and 2*. Annual Review of Pharmacology & Toxicology, 1998. **38**(1): p. 97-120.
- [9] Maree A O, Curtin R J, Chubb A, et al., *Cyclooxygenase-1 haplotype modulates platelet response to aspirin*. J Thromb Haemost, 2005. **3**(10): p. 2340-5.
- [10] Cipollone F, Prontera C, Pini B, et al., *Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability*. Circulation, 2001. **104**(8): p. 921-7.
- [11] Kohsaka S, Volcik K A, Folsom A R, et al., *Increased risk of incident stroke associated with the cyclooxygenase 2 (COX-2) G-765C polymorphism in African-Americans: The Atherosclerosis Risk in Communities Study*. Atherosclerosis, 2008. **196**(2): p. 926-930.
- [12] Donatella C, Laura F, Gianluca T, et al., *The COX-2 G/C -765 polymorphism may modulate the occurrence of cerebrovascular ischemia*. Blood Coagulation & Fibrinolysis An International Journal in Haemostasis & Thrombosis, 2006. **17**(2): p. 93-6.
- [13] Francesco C, Elena T, Stefano M, et al., *A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke*. Jama the Journal of the American Medical Association, 2004. **291**(18): p. 2221-8.
- [14] Cao L, Zhang Z, Sun W, et al., *Impacts of COX-1 gene polymorphisms on vascular outcomes in patients with ischemic stroke and treated with aspirin*. Gene, 2014. **546**(2): p. 172-6.
- [15] Kim D H, Ahn W Y, Kim D K, et al., *A Promoter polymorphism (rs17222919, -1316T/G) of ALOX5AP is associated with intracerebral hemorrhage in Korean population*. Prostaglandins Leukot Essent Fatty Acids, 2011. **85**(3-4): p. 115-20.
- [16] Li W, Xu J, Wang X, et al., *Cyclooxygenase-2 (COX-2) G-765C is a protective factor for coronary artery disease but not for ischemic stroke: a meta-analysis*. Atherosclerosis, 2009. **207**(2): p. 492-5.
- [17] Chen G Z, Shan X Y, Cheng G P, et al., *Cyclooxygenase-2 genetic polymorphism and stroke subtypes in Chinese*. J Mol Neurosci, 2013. **51**(2): p. 467-73.
- [18] Phillips P C, *The language of gene interaction*. Genetics, 1998. **149**(3): p. 1167-1171.
- [19] *Stroke-1989. Recommendations on stroke prevention, diagnosis, and therapy. Report of the WHO Task Force on Stroke and other Cerebrovascular Disorders*. Stroke, 1989. **20**(10): p. 1407-31.

- [20] Adams H P, Bendixen B H, Kappelle L J, et al., *Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment*. Stroke, 1993. **24**(1): p. 35-41.
- [21] Hu D Y, Ding R J, *Interpretation of the guidelines for prevention and treatments of dyslipidemia in Chinese adults*. Journal of Chinese medicine, 2010. 47(9): p. 723-724. [in Chinese]
- [22] Hallstrom A P, Cobb L A, and Ray R, . *Smoking as a risk factor for recurrence of sudden cardiac arrest*. New England Journal of Medicine, 1986. **314**(5): p. 271-5.
- [23] Langaee T, Ronaghi M, *Genetic variation analyses by Pyrosequencing*. Mutat Res, 2005. **573**(1-2): p. 96-102.
- [24] Tetsuya K, Atsuro M, Hayato I, et al., *Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2*. European Journal of Biochemistry, 1994. **221**(3): p. 889-897.
- [25] Calder P C, *Polyunsaturated fatty acids and inflammatory processes: New twists in an old tale*. Biochimie, 2009. **91**(6): p. 791–795.
- [26] Vucević D, Radak D, Radosavljević T, et al., *[Inflammatory process in atherogenesis: new facts about old flame]*. Medicinski Pregled, 2012. **65**(9-10): p. 388-395.
- [27] Yi X Y, Zhou Q, Lin J, et al., *Interaction between ALOX5AP-SG13S114A/T and COX-2-765G/C increases susceptibility to cerebral infarction in a Chinese population*. Genet Mol Res, 2013. **12**(2): p. 1660-9.
- [28] Lemaitre R N, Rice K, Marcianti K, et al., *Variation in eicosanoid genes, non-fatal myocardial infarction and ischemic stroke*. Atherosclerosis, 2009. **204**(2): p. e58-63.
- [29] Anika D, Sarvendra Vikram S, Charanjeet Singh S, et al., *Cyclooxygenase 2 gene polymorphisms and chronic periodontitis in a North Indian population: a pilot study*. Journal of Periodontal & Implant Science, 2012. **42**(5): p. 151-7.
- [30] Guo S, Li X, Gao M, et al., *Synergistic association of PTGS2 and CYP2E1 genetic polymorphisms with lung cancer risk in northeastern Chinese*. PLoS One, 2012. **7**(6): p. e39814.
- [31] Yafeng W, Heping J, Tianyun L, et al., *Cyclooxygenase-2 -1195G>A (rs689466) polymorphism and cancer susceptibility: an updated meta-analysis involving 50,672 subjects*. International Journal of Clinical & Experimental Medicine, 2015. **8**(8): p. 12448-62.
- [32] Chen Z Y, Li S S, li J, et al., *Cyclooxygenase-2 genetic polymorphism and stroke subtypes in Chinese Han population*. Journal of Chinese general medicine, 2014(17): p. 1959-1963. [in Chinese].
- [33] Du D H, Wu J, Gao P, et al., *Cyclooxygenase-2 genetic polymorphism and stroke*. Journal of Stroke and Neurological disorders, 2008. **25**(1): p. 49-52. [in Chinese]

Tables

Table 1 Baseline Characteristics for INVEST-GENES Participants

Characteristic	Control group(n=903)	IS group (n=1078)	P value
Age[years]	57.0±14.9	64.4±12.3	0.486
Sex(male%)	474(52.5)	677(62.8)	< 10⁻³
Hypertension (%)	154(17.1)	729(67.6)	< 10⁻³
Diabetes [%]	59(6.5)	361(33.5)	< 10⁻³
Hyperlipidemia (%)	90(10.0)	177(16.4)	< 10⁻³
Coronary heart disease [%]	10(1.1)	115(10.7)	< 10⁻³
Smoking [%]	244(27.0)	369 (34.2)	0.001
Alcohol consumption[%]	175(19.6)	235(21.9)	0.214
TG[mmol/L]	1.50±1.13	2.27±24.2	0.342
TC(mmol/L)	4.36±1.03	4.27±2.73	0.311
HDL-C(mmol/L)	1.36±0.43	1.25±0.50	< 10⁻³
LDL-C(mmol/L)	2.73±7.05	2.47±0.96	0.230
Fibrinogen levels [mmol/L]	2.20±1.59	3.16±1.00	< 10⁻³
Plt[10⁹/L]	178.5±72.1	169.0.±66.70	0.021

Characteristic	LAA group (n=405)	CES group(n=136)	SVO group[n=537]	P value
Age[years]	63.2±12.6	64.5±12.9	64.9±11.9	0.079
Sex(male%)	274(67.7)	62(45.6)	341(63.5)	< 10⁻³
Hypertension (%)	268(66.2)	65(47.8)	396(67.6)	< 10⁻³
Diabetes [%]	132(32.6)	24(17.6)	205(38.2)	< 10⁻³
Hyperlipidemia (%)	68(16.8)	13(9.6)	96(17.9)	0.063
Coronary heart disease [%]	45(11.1)	18(13.2)	52(9.7)	0.457
Smoking [%]	162(40.0)	25(18.4)	182(33.9)	< 10⁻³
Alcohol consumption[%]	102 (25.2)	17(12.6)	116(21.7)	0.009
TG[mmol/L]	1.65±1.22	1.26±0.66	2.52±27.79	0.042
TC(mmol/L)	4.51±4.88	4.00±1.58	4.21±1.15	0.367
HDL-C(mmol/L)	1.24±0.68	1.30±0.43	1.24±0.40	0.926
LDL-C(mmol/L)	2.44±0.94	2.64±3.87	2.49±0.99	0.084
Fibrinogen levels [mmol/L]	3.22±0.97	2.98±1.04	3.16±1.00	0.012
Plt[10⁹/L]	171.2±63.5	151.5±61.0	171.0±67.2	0.003

^a count data[mean±SD, measurement data(%)

^b $P < 0.05$ in bold

Table 2 Genotype and allele frequency distributions of SNPs in IS and controls

rs5788	Control group	IS group			LAA group		CES group		SVO group		
		n[%] ^a	<i>P</i> value	OR(95%CI)	<i>P</i> value	OR(95%CI)	<i>P</i> value	OR(95%CI)	<i>P</i> value	OR(95%CI)	
<i>Genotype</i>											
	CC	810 (89.7)	974 (90.4)	-	Reference	-	Reference	-	Reference	-	Reference
	CA	89 (9.9)	102 (9.5)	0.384	2.634 (0.297-23.332)	0.657	0.894 (0.545-1.466)	0.465	1.254 (0.684-2.298)	0.433	0.824 (0.507-1.338)
	AA	4 (0.4)	2 (0.2)	0.426	2.450 (0.270-22.255)	0.818	0.742 (0.058-9.471)	NA	-	0.539	0.380 (0.017-8.288)
	CA+AA vs CC			0.600	0.907 (0.629-1.307) ^b	0.634	0.888 (0.546-1.446)	0.525	1.216 (0.665-2.224) ^b	0.383	0.808 (0.500-1.305)
	AA vs CC+CA			0.388	0.382 (0.043-3.387)	0.825	0.750 (0.059-9.572)	NA	-	0.546	0.386 (0.018-8.454)
<i>Allele</i>											
	C	1709 (94.6)	2050 (95.1)	-	Reference	-	Reference	-	Reference	-	Reference
	A	97 (5.4)	106 (4.9)	0.498	0.884 (0.618-1.263)	0.510	0.851 (0.528-1.374)	0.586	1.173 (0.660-2.085)	0.413	0.824 (0.519-1.309)

^a Using multivariate analysis after adjusting for age, gender and traditional risk factors

^b *P* < 0.05 in bold

^c NA=not available

^d Reference: means allele homozygote as a reference

rs1330344	Control group	IS group			LAA group		CES group		SVO group		
		n[%]	P value	OR(95%CI)	P value	OR(95%CI)	P value	OR(95%CI)	P value	OR(95%CI)	
<i>Genotype</i>											
	GG	126	177	-	Reference	-	Reference	-	Reference	-	Reference
		(14.0)	(16.4)								
	GA	456	510	0.350	0.827	0.426	0.815	0.503	0.809	0.207	0.739
		(50.5)	(47.3)		(0.555-1.232)		(0.402-1.350)		(0.436-1.503)		(0.463-1.182)
	AA	321	391	0.044	0.657	0.108	0.652	0.043	0.506	0.048	0.616
		(35.5)	(36.3)		(0.437-0.988)		(0.387-1.099)		(0.262-0.978)		(0.382-0.995)
	GA+AA vs GG			0.133	0.794	0.239	0.781	0.178	0.699	0.050	0.690
					(0.587-1.073)		(0.517-1.179)		(0.415-1.177)		(0.475-1.000)
	AA vs GG+GA			0.588	0.939	0.623	0.927	0.132	0.723	0.698	0.944
					(0.748-1.179)		(0.685-1.254)		(0.474-1.102)		(0.708-1.260)
<i>Allele</i>											
	G	708	864	-	Reference	-	Reference	-	Reference	-	Reference
		(39.2)	(40.1)								
	A	1098	1292	0.029	0.812	0.034	0.778	0.023	0.702	0.097	0.829
		(60.8)	(59.9)		(0.675-0.978)		(0.618-0.981)		(0.518-0.951)		(0.665-1.035)

Using multivariate analysis after adjusting for age, gender and traditional risk factors

^b $P < 0.05$ in bold

^c Reference: means allele homozygote as a reference

rs3842788	Control group			<i>IS</i> group		<i>LAA</i> group		<i>CES</i> group		<i>SVO</i> group	
		n[%]	n[%]	<i>P</i> value	OR(95%CI)	<i>P</i> value	OR(95%CI)	<i>P</i> value	OR(95%CI)	<i>P</i> value	OR(95%CI)
<i>Genotype</i>											
	GG	795 (88.0)	890 (82.6)	-	Reference	-	Reference	-	Reference	-	Reference
	GA	97 (10.7)	120 (11.1)	0.337	0.821 (0.549-1.228)	0.122	0.652 (0.379-1.122)	0.861	0.944 (0.495-1.801)	0.591	0.876 (0.540-1.420)
	AA	11 (1.3)	68 (6.3)	0.165	5.127 (0.511-5.428)	0.128	7.858 (0.552-111.969)	0.082	9.758 (0.748-12.273)	0.326	4.586 (0.219-5.902)
	GA+AAvs GG			0.487	0.868 (0.583-1.293)	0.206	0.711 (0.419-1.207)	0.882	1.048 (0.562-1.955)	0.692	0.908 (0.563-1.465)
	AA vs GG+GA			0.016	5.203 (1.519-5.159)	0.121	8.167 (0.573-16.414)	0.041	9.821 (2.754-12.832)	0.025	4.603 (1.220-5.201)
<i>Allele</i>											
	G	1687 (93.4)	1900 (88.1)	-	Reference	-	Reference	-	Reference	-	Reference
	A	119 (6.6)	256 (11.9)	0.699	0.928 (0.635-1.355)	0.354	0.789 (0.479-1.302)	0.620	1.157 (0.650-2.057)	0.817	0.947 (0.600-1.496)

^a Using multivariate analysis after adjusting for age, gender and traditional risk factors

^b *P* < 0.05 in bold

^c Reference: means allele homozygote as a reference

rs20417	Control group	IS group			LAA group			CES group			SVO group	
		n(%)	P value	OR(95%CI)	P value	OR(95%CI)	P value	OR(95%CI)	P value	OR(95%CI)		
<i>Genotype</i>												
GG	812	977	-	Reference	-	Reference	-	Reference	-	Reference		
	(89.9)	(90.6)										
GC	87	97	0.680	1.080	0.424	1.223	0.812	1.084	0.423	1.211		
	(9.6)	(9.0)		(0.748-1.561)		(0.746-2.006)		(0.556-2.114)		(0.758-1.935)		
CC	4	4	0.341	421	0.528	0.443	0.479	0.335	0.528	0.499		
	(0.4)	(0.4)		(0.071-2.500)		(0.035-5.560)		(0.016-6.937)		(0.058-4.315)		
GC+CC vs GG			0.820	1.043	0.513	1.177	0.953	1.020	0.513	1.166		
				(0.726-1.498)		(0.723-1.915)		(0.528-1.970)		(0.736-1.848)		
CC vs GG+GC			0.378	0.418	0.519	0.436	0.477	0.334	0.518	0.492		
				(0.070-2.482)		(0.035-5.460)		(0.016-6.899)		(0.057-4.239)		
<i>Allele</i>												
G	1711	2051	-	Reference	-	Reference	-	Reference	-	Reference		
	(94.7)	(95.1)										
C	95	105	0.952	0.987	0.630	1.137	0.963	0.984	0.646	1.124		
	(5.3)	(4.9)		(0.655-1.489)		(0.675-1.914)		(0.504-1.924)		(0.684-1.847)		

^a Using multivariate analysis after adjusting for age, gender and traditional risk factors

^b $P < 0.05$ in bold

^c NA=not available

^d Reference: means allele homozygote as a reference

rs689466	Control group	IS group			LAA group		CES group		SVO group		
		n[%]	P value	OR(95%CI)	P value	OR(95%CI)	P value	OR(95%CI)	P value	OR(95%CI)	
<i>Genotype</i>											
	GG	189	241	-	Reference	-	Reference	-	Reference	-	Reference
		(20.9)	(22.4)								
	GA	472	519	0.408	0.888	0.435	0.861	0.676	1.116	0.230	0.805
		(52.3)	(48.1)		(0.671-1.176)		(0.592-1.253)		(0.666-1.872)		(0.565-1.147)
	AA	242	318	0.535	1.104	0.262	1.266	0.871	1.050	0.883	1.030
		(26.8)	(29.5)		(0.807-1.511)		(0.838-1.910)		(0.581-1.897)		(0.692-1.533)
	GA+AA vs GG			0.758	0.959	0.960	0.991	0.791	1.095	0.438	0.876
					(0.735-1.251)		(0.697-1.409)		(0.667-1.797)		(0.627-1.224)
	AA vs GG+GA			0.140	1.201	0.038	1.404	0.890	0.969	0.251	1.200
					(0.941-1.531)		(1.019-1.934)		(0.617-1.520)		(0.879-1.638)
<i>Allele</i>											
	G	850	1001	-	Reference	-	Reference	-	Reference	-	Reference
		(47.1)	(46.4)								
	A	956	1155	0.969	0.996	0.541	1.076	0.799	0.962	0.678	0.954
		(52.9)	(53.6)		(0.829-1.198)		(0.851-1.360)		(0.712-1.300)		(0.764-1.192)

Using multivariate analysis after adjusting for age, gender and traditional risk factors

^b $P < 0.05$ in bold

^c Reference: means allele homozygote as a reference

Table 3 MDR models of gene-gene interactions between three SNPs

SNP	IS					LAA				
	Best candidate model	Training accuracy	Testing accuracy	CVC	Permutation test P value	Best candidate model	Training accuracy	Testing accuracy	CVC	Permutation test P value
1	SNP3	0.5216	0.4981	7	0.206	SNP3	0.5342	0.5342	10/10	0.4270
2	SNP1	0.5375	0.5211	10	0.300	SNP1	0.5504	0.5346	10/10	0.8400
3	SNP3	0.5445	0.5176	10	0.330	SNP3	0.5591	0.5185	10/10	0.5600
	SNP1					SNP1				
	SNP2					SNP2				
	SNP3					SNP3				

SNP	CES					SVO				
	Best candidate model	Training accuracy	Testing accuracy	CVC	Permutation test <i>P</i> value	Best candidate model	Training accuracy	Testing accuracy	CVC	Permutation test <i>P</i> value
1	SNP1	0.5228	0.4834	5/10	0.7600 - 0.7610	SNP1	0.53	0.53	10/10	0.8520
2	SNP1	0.5383	0.4776	10/10	0.9510	SNP1	0.5428	0.5304	10/10	0.0050 - 0.0060
3	SNP3 SNP1	0.5552	0.4592	10/10	0.7990 - 0.8000	SNP3 SNP1	0.5496	0.5125	10/10	0.0190 - 0.0200
	SNP2 SNP3					SNP2 SNP3				

^a *P*<0.05 in bold

^b COX-1 rs1330344, rs3842788 COX-2 rs689466 signed as SNP1-3

^c CVC cross-validation consistency

Table 4 Additive effect analysis between three SNPs

Risk loci	control n(%)	IS			LAA		
		n(%)	OR(95% CI)	<i>P</i> value	n(%)	OR(95% CI)	<i>P</i> value
0	22(2.4)	32(3.0)	Reference		13(3.2)	Reference	
1	230(25.5)	294(27.3)	0.856(0.341-2.151)	0.741	105(25.9)	0.646(0.215-1.942)	0.437
2	586(64.9)	694(64.4)	0.752(0.323-1.752)	0.509	270(66.7)	0.587(0.216-1.595)	0.296
3	65(7.2)	58(5.4)	0.400(0.144-1.111)	0.079	17(4.2)	0.231(0.056-0.951)	0.052

Risk loci	control n(%)	CES			SVO		
		n(%)	OR(95% CI)	<i>P</i> value	n(%)	OR(95% CI)	<i>P</i> value
0	22(2.4)	4(2.9)	Reference		15(2.8)	Reference	
1	230(25.5)	33(24.3)	0.881(0.231-3.645)	0.861	156(29.1)	1.178(0.388-3.576)	0.773
2	586(64.9)	88(64.7)	0.677(0.183-2.502)	0.558	336(62.6)	0.747(0.272-2.050)	0.572
3	65(7.2)	11(8.1)	0.220(0.023-2.147)	0.193	30(5.6)	0.493(0.148-1.644)	0.250

^a Using multivariate analysis after adjusting for age, gender and traditional risk factors